Compare TG Therapeutics Inc (TGTX) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Wheaton Precious Metals Corp — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Wheaton Precious Metals Corp trades at $157.31 (market cap $70.35B). The key difference: Wheaton Precious Metals Corp is far larger — about 8.2× TG Therapeutics Inc's market cap, and Wheaton Precious Metals Corp pays a 0.5% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WPM | |
|---|---|---|
Market Cap | $8.53B | $70.35B |
Sector | Health | Basic Materials |
52-Week High | $59.06 | $165.72 |
52-Week Low | $26.94 | $94.37 |
Enterprise Value | $8.74B | $72.23B |
Dividend Yield | — | 0.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Wheaton Precious Metals (WPM) trades at $155.11, up 0.08% on the day, with a bullish technical signal from moving averages and strong fundamental performance. Recent earnings beats, including Q2 2026 EPS of $1.19 versus $1.15 expected, and record revenue of $2.31 billion in 2025 underscore robust operational momentum. The company's royalty and streaming model continues to deliver high margins, with a net income margin of 64.66% in 2025.
The outlook remains positive, supported by an 80% analyst buy rating and a consensus price target of $161.75, though risks include exposure to commodity price volatility and significant capital expenditures projected for 2026. The stock's current valuation multiples, such as a P/E of 34.41, reflect premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
